로사이돌프만병(RDD) 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 유형별(고전적 로사이돌프만병(RDD), 절외 로사이돌프만병(RDD)), 시술 유형별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Global Rosai-Dorfman Disease (RDD) market was valued at USD 647.05 million in 2024 and is projected to reach USD 962.66 million by 2030, expanding at a compound annual growth rate (CAGR) of 6.82% over the forecast period. This market represents a specialized yet vital segment of the healthcare industry, focusing on the diagnosis, treatment, and ongoing research of Rosai-Dorfman Disease-a rare, non-malignant disorder also known as sinus histiocytosis with massive lymphadenopathy (SHML).

RDD is characterized by the excessive proliferation and accumulation of histiocytes-a type of white blood cell-primarily within lymph nodes, though it may also affect other tissues and organs. Despite its rarity, growing global awareness, advancements in diagnostic technologies, and the pursuit of effective treatment strategies have accelerated market growth.

Key Drivers

Rising Incidence and Diagnostic Advancements

While Rosai-Dorfman Disease remains an uncommon condition-with an estimated prevalence of 1 in 200,000 individuals and approximately 100 new cases reported annually in the United States-enhanced diagnostic capabilities have led to increased identification of the disease globally. Innovations in imaging techniques, histopathology, and molecular diagnostics have improved the accuracy and timeliness of RDD diagnoses, contributing to a higher reported case volume and driving demand for targeted therapeutic interventions.

This growing recognition has fueled research and development activities aimed at creating specialized diagnostic tools and treatments. Recent discoveries, including the identification of genetic mutations such as BRAF-V600E in select RDD patients, have opened new opportunities for precision medicine and personalized treatment strategies. As a result, pharmaceutical firms and healthcare providers are investing in therapies tailored specifically to the clinical and biological characteristics of RDD.

The market spans a broad range of offerings including diagnostic assays, imaging systems, pharmaceuticals, and supportive care solutions. Collaborative efforts among pharmaceutical companies, academic institutions, and clinical providers are crucial in advancing research, uncovering disease mechanisms, exploring potential biomarkers, and developing innovative treatments.

Key Challenges

Low Disease Prevalence and Limited Awareness

A significant barrier to market development is the exceptionally low prevalence of RDD, compounded by limited awareness among healthcare professionals. The rarity of the condition often leads to misdiagnosis or delayed diagnosis, as its clinical presentation may mimic other, more common diseases. RDD can manifest with a wide spectrum of symptoms, from asymptomatic lymph node enlargement to extensive organ involvement, further complicating timely detection.

Infrequent clinical encounters with RDD contribute to a general unfamiliarity among physicians, hindering prompt and accurate diagnosis. Additionally, the lack of widespread awareness impacts funding and investment in RDD-specific research, limiting advancements in diagnostic and therapeutic innovations. This underinvestment challenges the development of effective, targeted interventions and impedes the broader understanding of the disease's pathophysiology.

Key Market Trends

Adoption of Immunohistochemistry and Molecular Profiling

The market is witnessing a paradigm shift toward precision diagnostics, underscored by the increasing use of immunohistochemistry (IHC) and molecular profiling. These technologies are becoming standard in identifying and confirming RDD cases with greater accuracy. IHC techniques enable the detection of disease-specific protein markers such as S100 and CD68, facilitating differentiation from other histiocytic and lymphoproliferative disorders.

Simultaneously, molecular profiling-through platforms such as next-generation sequencing (NGS)-is uncovering recurrent mutations (e.g., KRAS, MAP2K1) associated with RDD pathogenesis. These insights are paving the way for personalized therapeutic approaches, particularly for patients with refractory or recurrent disease.

As molecular diagnostic tools become more accessible and cost-effective, their adoption is expanding across both developed and emerging healthcare markets. Institutions are integrating these technologies into clinical practice, not only improving diagnostic precision but also enhancing patient monitoring and prognosis assessment.

Key Market Players

• Koninklijke Philips N.V.
• GE HealthCare
• Canon Inc
• Siemens Healthineers
• SternMed GmbH
• Jubilant Cadista Pharmaceuticals Inc
• LGM Pharma
• Henan Lihua Pharmaceutical Co., Ltd
• Niksan Pharmaceutical
• Sandoz Canada Inc

Report Scope:

In this report, the Global Rosai-Dorfman Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Rosai-Dorfman Disease Market, By Type:

• Classic (nodal) Rosai-Dorfman disease
• Extranodal Rosai-Dorfman disease

Global Rosai-Dorfman Disease Market, By Route of Administration:

• Oral
• Parenteral
• Sublingual
• Nasal

Global Rosai-Dorfman Disease Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centres
• Others

Global Rosai-Dorfman Disease Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rosai-Dorfman Disease Market.

Available Customizations:

Global Rosai-Dorfman Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rosai-Dorfman Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Classic (nodal) Rosai-Dorfman disease, Extranodal Rosai-Dorfman disease)
  • 5.2.2. By Procedure Type (Diagnosis, Treatment)
  • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centres, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Rosai-Dorfman Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Procedure Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Rosai-Dorfman Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Procedure Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Mexico Rosai-Dorfman Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Procedure Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Canada Rosai-Dorfman Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Procedure Type
      • 6.3.3.2.3. By End User

7. Europe Rosai-Dorfman Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Procedure Type
  • 7.2.3. By End User
  • 7.2.4. By Age Group
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Rosai-Dorfman Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Procedure Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Rosai-Dorfman Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Procedure Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Rosai-Dorfman Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Procedure Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Rosai-Dorfman Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Procedure Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Rosai-Dorfman Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Procedure Type
      • 7.3.5.2.3. By End User

8. Asia-Pacific Rosai-Dorfman Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Procedure Type
  • 8.2.3. By End User
  • 8.2.4. By Age Group
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Rosai-Dorfman Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Procedure Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Rosai-Dorfman Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Procedure Type
      • 8.3.2.2.3. By End User
  • 8.3.3. South Korea Rosai-Dorfman Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Procedure Type
      • 8.3.3.2.3. By End User
  • 8.3.4. Japan Rosai-Dorfman Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Procedure Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Rosai-Dorfman Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Procedure Type
      • 8.3.5.2.3. By End User

9. South America Rosai-Dorfman Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Procedure Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Rosai-Dorfman Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Procedure Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Rosai-Dorfman Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Procedure Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Rosai-Dorfman Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Procedure Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Rosai-Dorfman Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Procedure Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Rosai-Dorfman Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Procedure Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Rosai-Dorfman Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Procedure Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Rosai-Dorfman Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Procedure Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Koninklijke Philips N.V.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. GE HealthCare
• 15.3. Canon Inc
• 15.4. Siemens Healthineers
• 15.5. SternMed GmbH
• 15.6. Jubilant Cadista Pharmaceuticals Inc
• 15.7. LGM Pharma
• 15.8. Henan Lihua Pharmaceutical Co., Ltd
• 15.9. Niksan Pharmaceutical
• 15.10. Sandoz Canada Inc

16. Strategic Recommendations

17. About Us & Disclaimer